paclitaxel trial summary

Acute myocardial infarction

All type of patients: 3 trials - PASSION - HAAMU-STENT - HORIZONS-AMI Stent

No demonstrated result

suggested target-vessel revascularization by 35% (not demonstrated)

suggested 2 yr TLR by 42% (not demonstrated)

suggested target lesion revascularisation by 39% (not demonstrated)

suggested angiographic restenosis by 56% (not demonstrated)

Advanced breast cancer (metastatic)

All type of patients: 16 trials - CLGB 9840 (Seidman) - Gradishar - Fountzilas - Frasci - Frasci - Sikov - Khoo - Jassem - ANZ TITG - Dieras - ECOG E1193 (B) - EORTC 10923 - TOG - Talbot - CECOG BM1 - UKCCCR AB01

No demonstrated result

Coronary artery disease

Acute myocardial infarction: 3 trials - PASSION - HAAMU-STENT - HORIZONS-AMI Stent

No demonstrated result

suggested target-vessel revascularization by 35% (not demonstrated)

suggested 2 yr TLR by 42% (not demonstrated)

suggested target lesion revascularisation by 39% (not demonstrated)

suggested angiographic restenosis by 56% (not demonstrated)

See more clinical conditions

All type of patient: 19 trials - TAXUS I - TAXUS II - TAXUS IV - ASPECT - ELUTES - DELIVER - PATENCY - SCORE - TAXUS V (all patients) - TAXUS VI - PASSION - HAAMU-STENT - PERSEUS Workhorse - BASKET-SAVAGE - FRE-RACE - SYNTAX - VELETI - PEPCAD IV - ISAR-DESIRE (PES vs PTCA)

No demonstrated result

suggested MACE by 33% (not demonstrated)

suggested target-vessel revascularization by 39% (not demonstrated)

suggested target lesion revascularisation by 56% (not demonstrated)

suggested in-lesion binary restenosis by 70% (not demonstrated)

suggested angiographic restenosis by 69% (not demonstrated)

No demonstrated result

sub acute stent thrombosis (1-30 days) by 496% (harmful effect)

suggested cardiac death by 82% (not demonstrated)

suggested MACE by 50% (not demonstrated)

suggested 2 yr MACE by 44% (not demonstrated)

suggested 2 yr TLR by 103% (not demonstrated)

suggested target lesion revascularisation by 132% (not demonstrated)

suggested CABG by 126% (not demonstrated)

suggested late stent thrombosis (31days - 1year) by 57% (not demonstrated)

No demonstrated result

suggested angiographic restenosis by 35% (not demonstrated)

All type of patients: 21 trials - TAXUS I - TAXUS II - TAXUS IV - ASPECT - ELUTES - DELIVER - PATENCY - SCORE - TAXUS V (all patients) - TAXUS VI - PASSION - HAAMU-STENT - PERSEUS Workhorse - BASKET-SAVAGE - FRE-RACE - SYNTAX - VELETI - PEPCAD IV - Erglis - ISAR-DESIRE (PES vs PTCA) - HORIZONS-AMI Stent

No demonstrated result

suggested MACE by 25% (not demonstrated)

suggested target-vessel revascularization by 38% (not demonstrated)

suggested 2 yr TLR by 42% (not demonstrated)

suggested target lesion revascularisation by 52% (not demonstrated)

suggested in-lesion binary restenosis by 70% (not demonstrated)

suggested angiographic restenosis by 66% (not demonstrated)

No demonstrated result

sub acute stent thrombosis (1-30 days) by 496% (harmful effect)

suggested cardiac death by 82% (not demonstrated)

suggested MACE by 50% (not demonstrated)

suggested 2 yr MACE by 44% (not demonstrated)

suggested 2 yr TLR by 103% (not demonstrated)

suggested target lesion revascularisation by 132% (not demonstrated)

suggested CABG by 126% (not demonstrated)

suggested late stent thrombosis (31days - 1year) by 57% (not demonstrated)

No demonstrated result

suggested angiographic restenosis by 35% (not demonstrated)

Bypass graft lesion: 3 trials - BASKET-SAVAGE - VELETI - SOS

No demonstrated result

suggested target lesion revascularisation by 83% (not demonstrated)

No demonstrated result

Diabetic patients : 6 trials - TAXUS II (diabetics) - TAXUS IV (diabetics) - TAXUS V (diabetics) - TAXUS VI (diabetics) - PEPCAD IV - ISAR-test (diabetics)

No demonstrated result

suggested target lesion revascularisation by 59% (not demonstrated)

suggested angiographic restenosis by 83% (not demonstrated)

No demonstrated result

In stent restenosis: 1 trials - TAXUS V ISR

No demonstrated result

Long or complex lesion: 2 trials - TAXUS V (all patients) - SYNTAX

No demonstrated result

suggested MACE by 30% (not demonstrated)

suggested target-vessel revascularization by 30% (not demonstrated)

suggested target lesion revascularisation by 45% (not demonstrated)

suggested angiographic restenosis by 57% (not demonstrated)

No demonstrated result

sub acute stent thrombosis (1-30 days) by 496% (harmful effect)

suggested cardiac death by 82% (not demonstrated)

suggested MACE by 50% (not demonstrated)

suggested 2 yr MACE by 44% (not demonstrated)

suggested 2 yr TLR by 103% (not demonstrated)

suggested target lesion revascularisation by 132% (not demonstrated)

suggested CABG by 126% (not demonstrated)

suggested late stent thrombosis (31days - 1year) by 57% (not demonstrated)

Small vessels: 1 trials - TAXUS V small vessels sub groups

No demonstrated result

Unparticular patients: 10 trials - TAXUS I - TAXUS II - TAXUS IV - ASPECT - ELUTES - DELIVER - PATENCY - SCORE - PERSEUS Workhorse - FRE-RACE

No demonstrated result

suggested myocardial infarction (fatal and non fatal) by 180% (not demonstrated)

suggested MACE by 37% (not demonstrated)

suggested target-vessel revascularization by 50% (not demonstrated)

suggested target lesion revascularisation by 73% (not demonstrated)

suggested in-lesion binary restenosis by 70% (not demonstrated)

suggested angiographic restenosis by 76% (not demonstrated)

No demonstrated result

suggested angiographic restenosis by 35% (not demonstrated)

Unprotected left main artery stenosis: 1 trials - Erglis

No demonstrated result

suggested target lesion revascularisation by 88% (not demonstrated)

Head and neck cancer

All type of patients: 1 trials - Hitt paclitaxel

No demonstrated result

suggested complete response to study treatment by 75% (not demonstrated)

suggested complete response to induction CT by 147% (not demonstrated)

Stable angina

All type of patient: 16 trials - TAXUS I - TAXUS II - TAXUS IV - ASPECT - ELUTES - DELIVER - PATENCY - SCORE - TAXUS V (all patients) - TAXUS VI - PERSEUS Workhorse - BASKET-SAVAGE - FRE-RACE - SYNTAX - VELETI - PEPCAD IV

No demonstrated result

suggested MACE by 33% (not demonstrated)

suggested target-vessel revascularization by 39% (not demonstrated)

suggested target lesion revascularisation by 59% (not demonstrated)

suggested in-lesion binary restenosis by 70% (not demonstrated)

suggested angiographic restenosis by 69% (not demonstrated)

No demonstrated result

sub acute stent thrombosis (1-30 days) by 496% (harmful effect)

suggested cardiac death by 82% (not demonstrated)

suggested MACE by 50% (not demonstrated)

suggested 2 yr MACE by 44% (not demonstrated)

suggested 2 yr TLR by 103% (not demonstrated)

suggested target lesion revascularisation by 132% (not demonstrated)

suggested CABG by 126% (not demonstrated)

suggested late stent thrombosis (31days - 1year) by 57% (not demonstrated)

No demonstrated result

suggested angiographic restenosis by 35% (not demonstrated)

Paclitaxel Taxanes

Onxol - 7 epi Taxol - 7-epi-Taxol - Praxel - Paxene - Bris Taxol - Taxol A - Taxol - NSC125973 - NSC 125973 - NSC-125973 - Anzatax

Acute myocardial infarction

Advanced breast cancer (metastatic)

Coronary artery disease

Head and neck cancer

Stable angina